檢索結果 - Erika Hamilton

Refine Results
  1. 1
    Targeting CDK4/6 in patients with cancer

    Targeting CDK4/6 in patients with cancer 由 Erika Hamilton, Jeffrey R. Infante

    出版 2016
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  2. 2
    Targeting HER2-positive breast cancer: advances and future directions

    Targeting HER2-positive breast cancer: advances and future directions 由 Sandra M. Swain, Mythili Shastry, Erika Hamilton

    出版 2022
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer

    Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer 由 Mythili Shastry, Saya Jacob, Hope S. Rugo, Erika Hamilton

    出版 2022
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

    PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor–Positive Advanced Breast Cancer 由 Erika Hamilton, Rinath Jeselsohn, Linda T. Vahdat, Sara A. Hurvitz

    出版 2025
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  5. 5
    Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role

    Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging... 由 Maxwell R. Lloyd, Seth A. Wander, Erika Hamilton, Pedram Razavi, Aditya Bardia

    出版 2022
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  6. 6
    Rise of Antibody-Drug Conjugates: The Present and Future

    Rise of Antibody-Drug Conjugates: The Present and Future 由 Mythili Shastry, Avantika Gupta, Sarat Chandarlapaty, Matthew R. Young, Thomas Powles, Erika Hamilton

    出版 2023
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

    Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity 由 Devalingam Mahalingam, Judy S. Wang, Erika Hamilton, John Sarantopoulos, John Nemunaitis, Garry Weems, Laura Carter, Xiao Hu, Marshall T. Schreeder, H. Jeffrey Wilkins

    出版 2019
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer

    nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HE... 由 Erika Hamilton, Javier Cortés, Özgür Özyılkan, Shin‐Cheh Chen, Katarína Petráková, Alexey Manikhas, Guy Jérusalem, Roberto Hegg, Jens Huober, Wei Zhang, Yanyun Chen, Miguel Martín

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing

    Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing 由 Christina I. Herold, Vijaya Chadaram, Bercedis L. Peterson, P. Kelly Marcom, Judith O. Hopkins, Gretchen Kimmick, Justin Favaro, Erika Hamilton, Renee Welch, Sarah Bacus, Kimberly Blackwell

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

    Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes 由 Timothy A. Yap, Erika Hamilton, Todd M. Bauer, Ecaterina E. Dumbrava, Rinath Jeselsohn, Aaron Enke, Sabrina Hurley, Kevin K. Lin, Jenn Habeck, Heidi Giordano, Geoffrey I. Shapiro

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up

    Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up 由 Sylvia Adams, Jennifer R. Diamond, Erika Hamilton, Paula R. Pohlmann, Sara M. Tolaney, Ching‐Wei Chang, Wei Zhang, Koho Iizuka, Paul Foster, Luciana Molinero, Roel Funke, John D. Powderly

    出版 2018
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer

    First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer 由 Mark D. Pegram, Erika Hamilton, Antoinette R. Tan, Anna Maria Storniolo, Kemal Balic, Anton I. Rosenbaum, Meina Liang, Peng He, Shannon Marshall, Anita Scheuber, Mayukh Das, Manish R. Patel

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer

    A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer 由 Erika Hamilton, Manish R. Patel, Anne Armstrong, Richard D. Baird, Komal Jhaveri, Matthias Hoch, Teresa Klinowska, Justin P.O. Lindemann, Shethah Morgan, Gaia Schiavon, Hazel M. Weir, Seock‐Ah Im

    出版 2018
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    273O nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer

    273O nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer 由 Erika Hamilton, Javier Cortés, Özgür Özyılkan, S-C. Chen, Katarína Petráková, Alexey Manikhas, Guy Jérusalem, Roberto Hegg, Jens Huober, Sonya C. Chapman, Zhengyu Yang, Yongmei Chen, Erica L. Johnston, Miguel Martín

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    The evolution of cyclin dependent kinase inhibitors in the treatment of cancer

    The evolution of cyclin dependent kinase inhibitors in the treatment of cancer 由 Komal Jhaveri, Howard A Burris rd, Timothy A. Yap, Erika Hamilton, Hope S. Rugo, Jonathan W. Goldman, Stephen G. Dann, Feng Liu, Gilbert Y. Wong, Heike I. Krupka, Geoffrey I. Shapiro

    出版 2021
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  16. 16
    185P Safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) and active brain metastases (BM) in DESTINY-Breast07 (DB-07)

    185P Safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) and active brain metastases (BM) in... 由 C. Anders, S. Loi, Erika Hamilton, Komal Jhaveri, P. Schmid, Erhan Gökmen, S-A. Im, Cengiz Karaçin, Carlos H. Barrios, Y.H. Park, S. Uzunoğlu, Sarah E. Boston, Adam Konpa, S. Mondal, Fabrice André

    出版 2024
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors

    PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors 由 Timothy A. Yap, Atish D. Choudhury, Erika Hamilton, Lee S. Rosen, Kayla Stratton, M. Gordon, David Schaer, Lei Liu, L. Zhang, Rajendar K. Mittapalli, Wei Zhong, N. Soman, A. W. Tolcher

    出版 2024
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion

    Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion 由 Erika Hamilton, Kimberly Blackwell, Amy Hobeika, Timothy M. Clay, Gloria Broadwater, Xiu-Rong Ren, Wei Chen, Henry Castro, Frédéric Lehmann, Neil L. Spector, Jun-Ping Wei, Takuya Osada, H. Kim Lyerly

    出版 2012
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer 由 Siqing Fu, Bradley R. Corr, Kerry Culm-Merdek, Colleen Mockbee, Hagop Youssoufian, Robert Stagg, R. Wendel Naumann, Robert M. Wenham, Rafael D. Rosengarten, Laura E. Benjamin, Erika Hamilton, Kathleen N. Moore

    出版 2022
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer

    First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer 由 Nehal J. Lakhani, Daphne Stewart, Debra L. Richardson, Lauren Dockery, Linda Van Le, Justin Call, Fatima Rangwala, Guanfang Wang, Bo Ma, Simon Metenou, Jade Huguet, Elliot Offman, Lini Pandite, Erika Hamilton

    出版 2025
    獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: